Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Yasunori Oguma is active.

Publication


Featured researches published by Yasunori Oguma.


European Journal of Heart Failure | 2013

Adaptive servo-ventilation therapy improves cardiac sympathetic nerve activity in patients with heart failure.

Takashi Koyama; Hiroyuki Watanabe; Yoshikazu Tamura; Yasunori Oguma; Toshimitsu Kosaka; Hiroshi Ito

This study investigated whether abnormal cardiac sympathetic nerve activity (SNA) is associated with the severity of central sleep apnoea (CSA) and whether adaptive servo‐ventilation (ASV) therapy can improve cardiac SNA in heart failure (HF) patients with predominant CSA.


Lipids in Health and Disease | 2013

Comparison of anti-inflammatory effects and high-density lipoprotein cholesterol levels between therapy with quadruple-dose rosuvastatin and rosuvastatin combined with ezetimibe

Daisuke Yamazaki; Masaru Ishida; Hiroyuki Watanabe; Kiyoshi Nobori; Yasunori Oguma; Yutaka Terata; Takashi Koyama; Kenji Iino; Toshimitsu Kosaka; Hiroshi Ito

BackgroundStatins are frequently administered to reduce low-density lipoprotein cholesterol (LDL-C) and vascular inflammation, because LDL-C and high sensitive C-reactive protein (hs-CRP) are associated with high risk for cardiovascular events. When statins do not reduce LDL-C to desired levels in high-risk patients with coronary artery disease (CAD), ezetimibe can be added or the statin dose can be increased. However, which strategy is more effective for treating patients with CAD has not been established. The present study compares anti-inflammatory effects and lipid profiles in patients with CAD and similar LDL-C levels who were treated by increasing the statin dose or by adding ezetimibe to the original rosuvastatin dose to determine the optimal treatment for such patients.Methods46 patients with high-risk CAD and LDL-C and hs-CRP levels of >70 mg/dL and >1.0 mg/L, respectively, that were not improved by 4 weeks of rosuvastatin (2.5 mg/day) were randomly assigned to receive 10 mg (R10, n = 24) of rosuvastatin or 2.5 mg/day of rosuvastatin combined with 10 mg/day of ezetimibe (R2.5/E10, n = 22) for 12 weeks. The primary endpoint was a change in hs-CRP.ResultsBaseline characteristics did not significantly differ between the groups. At 12 weeks, LDL-C and inflammatory markers (hs-CRP, interleukin-6, tumour necrosis factor-alpha and pentraxin 3) also did not significantly differ between the two groups (LDL-C: R10 vs. R2.5/E10: -19.4 ± 14.2 vs. -22.4 ± 14.3 mg/dL). However, high-density lipoprotein cholesterol (HDL-C) was significantly improved in the R10, compared with R2.5/E10 group (4.6 ± 5.9 vs. 0.0 ± 6.7 mg/dL; p < 0.05).ConclusionBoth enhanced therapies exerted similar anti-inflammatory effects under an equal LDL-C reduction in patients with high-risk CAD despite 2.5 mg/day of rosuvastatin. However, R10 elevated HDL-C more effectively than R2.5/E10.Trial registrationUMIN000003746


Heart and Vessels | 2012

A free-floating left atrial thrombus develops intermittent entrapment in the mid-ventricle during diastole

Mikiko Fujiwara; Hiroyuki Watanabe; Yasunori Oguma; Genbu Yamaura; Kazuyuki Ishibashi; Hiroshi Yamamoto; Kiyoshi Nobori; Kenji Iino; Fumio Yamamoto; Hiroshi Ito

Free-floating left atrial thrombi are rare. Here we report a case of a 75-year-old woman with atrial fibrillation who was admitted for treatment of acute myocardial infarction. A free-floating left atrial thrombus was found incidentally on echocardiography. Ten days after percutaneous coronary intervention, the patient had mild faintness with transient hypotension, and it was found that the left atrial thrombus had developed intermittent entrapment in the mid-ventricle during diastole, with abrupt rebound back to the left atrial cavity during systole. Urgent removal of the thrombus was performed successfully. Although the free-floating thrombus had appeared to be spherical, like a ball thrombus, on echocardiography, the excised thrombus was pedunculated. A cut section revealed a laminated thrombus with an onion-skin-like appearance.


Neuroscience Letters | 1998

Optical imaging of the spontaneous neuronal activities in the male rat major pelvic ganglion following denervation of the pelvic nerve

Michiru Imaizumi; Yasunori Oguma; Masahito Kawatani

Measurement of groups of neuronal activities following pelvic nerve transection to the major pelvic ganglion (MPG) of the rat was performed using voltage-sensitive dye (RH795) and an optical recording system. In control MPG, averaged neuron diameters were 32.0 +/- 0.6 x 22.6 +/- 0.4 microm. Application of KCl (10-50 mM) to the ganglia exhibited excitation which increased in a dose-dependent fashion. Fluctuating membrane potentials were not observed in control ganglion neurons. After the denervation of pelvic nerve chronically (2-6 weeks), the spontaneous neuronal activities were recorded in 91% of the experiments (n = 32). The activity was occurring somewhat periodically (2-15 s). Averaged neuron diameters were 41.3 +/- 1.3 x 24.7 +/- 0.9 microm in denervated MPG which is significantly larger than control. Since average neuron size increased 4 weeks after the denervation, the new excitatory activities could have influenced the change of the neuron size. The new activities might produce contraction of target organs in the pelvic viscera.


Journal of Thoracic Disease | 2016

Tricuspid valve chordae tendineae as protective filter to prevent massive pulmonary embolism

Hiroyuki Watanabe; Mai Shimbo; Mai Terada; Hironori Kiso; Seiya Shimizu; Yasunori Oguma; Kenji Iino; Hiroshi Ito

Although several cases of thrombus-in-transit associated with pro-thrombotic conditions have been reported (1-3), a transit thrombus located in the right ventricular (RV) cavity is extremely rare (4,5). Here, we report a case of nephrotic syndrome (NS) with a RV thrombus-in-transit that threatened to cause a fatal pulmonary embolism (PE).


ASVIDE | 2016

A transesophageal echocardiographic image produced 4 days after initiating thrombolytic therapy

Hiroyuki Watanabe; Mai Shimbo; Mai Terada; Hironori Kiso; Seiya Shimizu; Yasunori Oguma; Kenji Iino; Hiroshi Ito


ASVIDE | 2016

Transthoracic echocardiography (TTE) and transesophageal echocardiography showing the disappearance of the right ventricle (RV) thrombus

Hiroyuki Watanabe; Mai Shimbo; Mai Terada; Hironori Kiso; Seiya Shimizu; Yasunori Oguma; Kenji Iino; Hiroshi Ito


ASVIDE | 2016

Transthoracic echocardiography (TTE) showing a largelobulated mass in the right ventricle (RV) cavity

Hiroyuki Watanabe; Mai Shimbo; Mai Terada; Hironori Kiso; Seiya Shimizu; Yasunori Oguma; Kenji Iino; Hiroshi Ito


Internal Medicine | 2014

Immunochemical fecal occult blood tests predict dual antiplatelet therapy discontinuation after coronary stenting.

Ken Ikeda; Takashi Koyama; Masaru Ishida; Megumi Okawa; Yasunori Oguma; Yutaka Terata; Kenji Iino; Toshimitsu Kosaka; Hiroyuki Watanabe; Hiroshi Ito


Journal of Cardiac Failure | 2012

Comparison of Inflammatory Markers and Lipid Profile Between High-dose Rosuvastatin Monotherapy and Ezetimibe / Rosuvastatin Combination Therapy

Daisuke Yamazaki; Masaru Ishida; Kiyoshi Nobori; Yasunori Oguma; Yutaka Terata; Takashi Koyama; Kenji Iino; Toshimitsu Kosaka; Hiroyuki Watanabe; Hiroshi Ito

Collaboration


Dive into the Yasunori Oguma's collaboration.

Top Co-Authors

Avatar

Hiroshi Ito

Fukushima Medical University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge